Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.109
Peer-review started: October 30, 2023
First decision: November 22, 2023
Revised: December 4, 2023
Accepted: January 12, 2024
Article in press: January 12, 2024
Published online: January 27, 2024
Processing time: 84 Days and 21.7 Hours
This letter comments on the article which reported that tenofovir alafenamide may increase blood lipid levels compared with entecavir in patients with chronic hepatitis B published on World J Hepatol 2023 August 27. We review the related research content, topic selection, methodology, conclusions, strengths and weaknesses of this article. And evaluate it in relation to other published relevant articles.
Core Tip: With the significant increase in the incidence of nonalcoholic fatty liver disease (NAFLD) in China, the number of patients with co-morbid chronic hepatitis B (CHB) and NAFLD has gradually increased. This letter comments on a published study which showned that CHB patients treated with tenofovir alafenamide (TAF) had higher levels of total cholesterol than CHB patients treated with entecavir; however, TAF-induced dyslipidemia did not increase the incidence of NAFLD. We comment on the article.